Immunotherapy in Liver Transplant Recipients with Advanced Solid Malignancies: A Three-Patient Case Series
Current Oncology · 16.10.2026 · 33 (10) · 623
DOI: 10.3390/curroncol33100623 ↗Kurz gefasst
Fallbericht in der Zeitschrift Current Oncology, online erschienen am 16.10.2026. Verfasst von Belinda Jiao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Gerald Bronfman Department of Oncology, McGill University, Montreal, QC H4A 3T2, Canada. Hauptthemen laut MEDLINE: Liver Transplantation, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The use of immune checkpoint inhibitors (ICIs) after liver transplantation (LT) remains controversial, because immune activation may cause allograft rejection. Evidence in non-hepatocellular carcinoma (HCC) malignancies is limited. We retrospectively reviewed three LT recipients treated with pembrolizumab for advanced non-HCC malignancies at the McGill University Health Centre; treatment began between May 2020 and January 2025, and follow-up was censored on 31 January 2026. A patient with PD-L1-negative non-small cell lung cancer (NSCLC) achieved stable disease for approximately seven months, whereas a patient with PD-L1-high NSCLC achieved a durable partial response with progression-free survival of approximately 36 months. A third patient with cutaneous squamous cell carcinoma achieved a near-complete radiologic and metabolic response after two cycles. Pembrolizumab was held after this response; subsequent liver-test abnormalities raised concern for graft injury, but biopsy showed no histologic rejection and supported treatment resumption. No clinical or biochemical evidence of rejection was observed in Cases 1 and 2. At cutoff, Case 3 was alive and receiving pembrolizumab after seven cycles. These cases support a cancer-specific, individualized risk-benefit assessment in which expected oncologic benefit, alternatives, graft history, immunosuppression, and acceptance of graft-loss risk guide multidisciplinary treatment and close graft surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gerald Bronfman Department of Oncology, McGill University, Montreal, QC H4A 3T2, Canada.
- Département d'oncologie médicale, Institut Gustave Roussy, 94805 Villejuif, France.
- Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, QC J1H 5H3, Canada.
- Cedars Cancer Centre, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
- Department of Oncology, St. Mary's Hospital Center, Montreal, QC H3T 0A2, Canada.
- Division of Gastroenterology & Hepatology, McGill University, Montreal, QC H4A 3J1, Canada.
ORCID-Profile: Belinda Jiao, Charles Vincent Rajadurai, Arielle Sabbah, Scott Owen, Xun Zhao
Zitieren
APA
Jiao, B., Rajadurai, C. V., Benizri, N., Sabbah, A., Owen, S., Esfahani, K., Deschenes, M., Wong, P., Zhao, X., & Asselah, J. (2026). Immunotherapy in Liver Transplant Recipients with Advanced Solid Malignancies: A Three-Patient Case Series. Current Oncology, 33(10), 623. https://doi.org/10.3390/curroncol33100623
Vancouver
Jiao B, Rajadurai CV, Benizri N, Sabbah A, Owen S, Esfahani K, et al. Immunotherapy in Liver Transplant Recipients with Advanced Solid Malignancies: A Three-Patient Case Series. Current Oncology. 2026;33(10):623. doi:10.3390/curroncol33100623
BibTeX
@article{Jiao2026,
author = {Jiao, Belinda and Rajadurai, Charles Vincent and Benizri, Nissim and Sabbah, Arielle and Owen, Scott and Esfahani, Khashayar and Deschenes, Marc and Wong, Philip and Zhao, Xun and Asselah, Jamil},
title = {Immunotherapy in Liver Transplant Recipients with Advanced Solid Malignancies: A Three-Patient Case Series},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {10},
pages = {623},
doi = {10.3390/curroncol33100623}
}
EUVIMED